7-(7-氨甲基-5-氮杂螺［2,4］庚烷-5-基)-1-环丙基-6-氟-8-甲氧基-1,4-二氢-4-氧代喹啉-3-羧酸及其类似物的合成与抗菌作用7-(7-氨甲基-5-氮杂螺［2,4］庚烷-5-基)-1-环丙基-6-氟-8-甲氧基-1,4-二氢-4-氧代喹啉-3-羧酸及其类似物的合成与抗菌作用

目的寻找新的广谱、高效、低毒喹诺酮类抗菌药物。方法设计合成7-(7-氨甲基-5-氮杂螺［2,4］庚烷-5-基)-1-环丙基-6-氟-8-甲氧基-1,4-二氢-4-氧代喹啉-3-羧酸及其类似物,测定其体内外活性。结果共合成了20个新化合物,经¹HNMR,MS和HRMS确证其结构。其中5个目标化合物(22～26)有广谱活性,尤其对革兰氏阳性菌具有很强的活性。其中化合物24对所试的13株革兰氏阳性菌的MIC值均0.03 mg·L^-1,其活性优于对照药克林沙星和加替沙星,对所试的6株革兰氏阴性菌,其活性相当于或低于对照药。结论化合物(22～26)值得进一步评价。     

5-氨基-6,8-二氟-1-(5-氟-2-吡啶基)-7-(3-甲基-1-哌嗪基)-1,4-二氢-4-氧代喹啉-3-羧酸及其类似物的合成及其抗菌作用

目的设计合成1-位为5-氟-2-吡啶基的吡酮酸衍生物,并对其抗菌活性进行初步评价.方法以2,3,4,5-四氟-6-硝基苯甲酰基乙酸乙酯和2,4,5-三氟-3-甲氧基苯甲酰基乙酸乙酯为原料,经多步反应合成8个5-氨基-6,8-二氟-1-(5-氟-2-吡啶基)-7-(3-甲基-1-哌嗪基)-1,4-二氢-4-氧代喹啉-3-羧酸及其类似物.结果共合成15个新化合物,经¹HNMR和MS确证其结构,其中8个(8-15)为目标物.结论8个目标物对金黄色葡萄球菌-16、大肠埃希氏菌-26和铜绿假单孢菌-17的体外活性均低于环丙沙星.     

dl-7-(4,4-二甲基-3-氨甲基-吡咯烷-1-基)-喹诺酮类化合物的合成与抗菌作用

目的寻找新的高效抗革兰氏阳性菌的喹诺酮类药物。方法设计合成了dl-7-(4,4-二甲基-3-氨甲基-吡咯烷-1-基)-1-环丙基-6-氟-8-甲氧基-1,4-二氢-4-氧代喹啉-3-羧酸及其类似物，测定其体外活性。结果共合成10个目标化合物，经¹H NMR，MS确证其结构。目标化合物具有良好的抗革兰氏阳性菌的活性，尤其是化合物22不仅对4株革兰氏阳性耐药菌(两株MRSA，两株MRSE)的活性表现突出，MIC值为0.015～0.5 mg·L^-1，其活性是加替沙星(MIC值为0.125～16 mg·L^-1)的4～128倍，而且，对铜绿假单孢菌03-5的MIC值为0.008 mg·L^-1，其活性是加替沙星(MIC值为0.03 mg·L^-1)的4倍。结论化合物22值得进一步深入评价。     

7—（3—羟基—1，5—二氮杂环庚烷—1—胺基）—1—环丙基—6—氟—1，4—二氢—4氧代喹啉—3—羧酸及其类似物的合成与抗菌活性

设计并合成了新化合物7－（3－羟基－1,5－二氮杂环庚烷－1－胺基）－1－环丙基－6－氟－1,4－二氢－4氧代喹啉－3－羧酸（5a)及其类似物5b-5d,采用标准二倍稀释法测定了其对26株有代表性的革兰氏阳性及革兰氏阴性菌的体外抗菌活性。结果表明化合物5a-5d对所测菌株的抑菌活性低于司帕沙星,而5a和5e则对革兰氏阳性菌金葡球菌有较高的活性,其最低抑菌浓度MIC值为0．125mg/L。     

7-{4-［2-［2-取代-4-((5S)-5-乙酰胺甲基-2-氧代-噁唑烷-3-基)苯基］乙基］哌嗪-1-基}-氟喹诺酮类化合物的合成与抗菌活性

目的寻找新型的噁唑烷酮-氟喹诺酮类抗菌药物。方法设计合成了7-{4-［2-［2-取代-4-((5S)-5-乙酰胺甲基-2-氧代-噁唑烷-3-基)苯基］乙基］哌嗪-1-基}-氟喹诺酮类化合物，测定其体外抗菌活性。结果共合成20个目标化合物，经^{1H NMR和MS确证结构。目标化合物具有较好的体外抗菌活性，尤其是化合物22，对屎肠球菌的抑制活性分别是吗啉噁酮和诺氟沙星的16倍和64倍，对金葡菌的抑制活性为吗啉噁酮的4倍。结论某些带有氟喹诺酮结构片段的噁唑烷酮类化合物抗菌活性加强。}     

莫西沙星8-二氟甲氧基类似物的合成与体内外抗菌作用

1-环丙基-6，7-二氟-8-甲氧基-1，4-二氢．4-氧代喹啉．3-羧酸乙酯依次经醚键断裂、酯化、二氟甲基醚化得1．环丙基-6，7-二氟-8-二氟甲氧基-1，4-二氢-4-氧代喹啉．3-羧酸乙酯，然后经过螫合、与[1S，6S]-2．叔丁氧羰基．2，8．二氮杂双环[4，3，0]壬烷缩合、最后脱除叔丁氧羰基保护得到1-环丙基．8．二氟甲氧基-7-[（1S，6S）．2，8．二氮杂双环[4，3，0]壬烷．8．基]-6-氟．1，4-二氢-4-氧代喹啉-3-羧酸。目标化合物的结构经核磁共振氢谱和质谱（ESI）所确证，并测定了其体内外抗菌作用，结果表明该化合物优于对照药环丙沙星，与莫西沙星相当或略优，尤其对肺炎链球菌29074的体内活性突出，值得深入评价。     

吡酮酸类抗菌药物的研究XIV.7,8-双取代-1-环丙基-6-甲基-1,4-二氢-4-氧代喹啉-3-羧酸类化合物的合成与构效关系

合成了18个1-环丙基-6-甲基- 7-取代氨基,8-位为H,Cl,NO₂,NH₂的6-位非氟吡酮酸类化合物,测定了它们对10株革兰氏阳性和革兰氏阴性细菌的MIC值,并与环丙沙星、诺氟沙星对照,讨论了它们的构效关系。     

5-三氟甲基-3-(4-甲基-1H-咪唑-1-基)苯胺的合成

3,5-二硝基三氟甲苯(2)与氟化四甲铵进行氟代反应,所得单氟中间体再与4-甲基-1H-咪唑进行取代反应得到5-三氟甲基-3-(4-甲基-1H-咪唑-1-基)-硝基苯(3),然后在Pd/C催化下氢化还原制得抗肿瘤药尼罗替尼的中间体5-三氟甲基-3-(4-甲基-1H-眯唑-1-基)-苯胺(1),总收率约50％(以2计).     

7-(取代-5-氮杂螺[2,4]庚烷-5-基)喹诺酮类化合物的合成与抗菌作用

为寻找新的广谱、高效、低毒喹诺酮类抗菌药物,本文设计合成了9个7-(7-甲基氨甲基-5-氮杂螺2,4庚烷-5-基)-1-环丙基-6-氟-1,4-二氢-4-氧代-1,8-萘啶-3-羧酸及其类似物,其结构均经1H-NMR、MS所确证,并测定了它们的体外抗菌活性。结果表明,9个目标物均具有广谱活性,其中化合物23、26、27对10株革兰氏阳性菌的MIC值为0.01～0.12μg/ml,其活性远优于对照药加替沙星(MIC值为0.12～1μg/ml)和环丙沙星(MIC值为0.25～4μg/ml)。对10株革兰氏阴性菌的MIC值为0.01～2μg/ml,其活性基本与对照药相当或更优。     

6-氟-4-喹诺酮类杂合分子的合成及体外抗菌活性研究

目的 筛选新型抗耐药的具有抗菌活性的6-氟-4-喹诺酮类杂合化合物。方法 以诺氟沙星和6-氟-4-喹诺酮-3-羧酸乙酯为主体，与异烟肼、妥曲珠利、青蒿素衍生物和1,2,4-三唑衍生物等结构单元进行杂合，设计了一系列新杂合分子，通过酰胺缩合、烷基化、Mannich反应以及Schiff反应等得到目标化合物。采用测定最小抑菌浓度法，测定目标化合物对革兰阳性菌-耐甲氧西林金黄色葡萄球菌(MRSA)和革兰阴性菌-铜绿假单胞菌(Pae)的体外抗菌活性。结果与结论合成了11个全新的6-氟-4-喹诺酮类杂合分子，所有目标化合物的结构经ESI-MS、¹H-NMR谱确证。体外抗菌活性测试结果表明绝大部分目标化合物具有一定的抗菌活性，其中化合物D对Pae表现出更好的抗菌活性(MIC值为1.0μg·mL^-1,优于阳性对照药诺氟沙星3.9μg·mL^-1);化合物J对MRSA表现出更好的抗菌活性(MIC值为4.2μg·mL^-1,优于阳性对照药诺氟沙星7.8μg·mL^-1)。结合修饰过的分子结构和反应位点，...     

Synthesis and antibacterial activity of 1-(substituted pyrrolyl)-7-(substituted amino)-6-fluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids.

Seventeen quinolone compounds characterized by having a fluorine atom at the 6-position, a substituted amino at the 7-position, and a substituted pyrrolyl at the 1-position were synthesized for the first time. The in vitro antibacterial activities of these compounds against Escherichia coli and Staphylococcus aureus were tested. Among these agents obtained, compound 24 showed significantly enhanced activity against S. aureus. The results indicate that there is much room for modifications at the N-1 position.     

1-烷基-6-氟-1,4-二氢-7-(4-酰基-1-哌嗪基)-4-氧代喹啉-3-羧酸类似物的合成及其抗菌活性

目的 设计合成具有广谱抗菌活性的含氟喹诺酮类化合物。方法 利用吡酮酸7位哌嗪基4位氮上存在的活性氢为反应修饰基点，与磺酰氯，酰氯，氯甲酸酯进行Schotten-Baumann酰基化反应设计合成一系列含有磺酰基、酰基和烷氧羰基类氟喹诺酮类似物。结果 合成了20个含有磺酰基、酰基和氧羰基的氟喹诺酮类似物，利用元素分析、核磁共振进行了结构确认。结论 合成了16个未见报道的新化合物，初步体外活性测试结果表明，其中的4个化合物有较高的生物活性。     

Synthesis, calcium-channel-blocking activity, and antihypertensive activity of 4-(diarylmethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds

A series of 4-(diarylmethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds were synthesized as calcium-channel blockers and antihypertensive agents. Compounds were evaluated for calcium-channel-blocking activity by determining their ability to antagonize calcium-induced contractions of isolated rabbit aortic strips. The most potent compounds were those with fluoro substituents in the 3- and/or 4-positions of both rings of the diphenylmethyl group. Bis(4-fluorophenyl)acetonitrile analogue 79 was similar in potency to bis(4-fluorophenyl)methyl compound 1. The methylene analogue of 1 (78) and derivatives of 1 that contained a hydroxyl (76), carbamoyl (80), amino (81), or acetamido (82) substituent on the methyl group were less potent. In most cases, substituents on the phenoxy ring, changes in the distance between the aryloxy group and the piperidine nitrogen, and the substitution of S, N(CH3), or CH2 for the oxygen atom of the aryloxy group had only a small to moderate effect on the potency. The best compounds in this series were more potent than verapamil, diltiazem, flunarizine, and lidoflazine, but were less potent than nifedipine. Compounds were evaluated for antihypertensive activity in spontaneously hypertensive rats (SHR) at an oral dose of 30 mg/kg. Of the 55 compounds tested, only nine produced a statistically significant (p less than 0.05) reduction in blood pressure greater than 20%; all of these compounds had fluoro substituents in both rings of the diphenylmethyl group. One of the most active compounds in the SHR at 30 mg/kg was 1-[4-[3-[4-[bis(3,4-difluorophenyl)methyl]-1- piperidinyl]propoxy]-3-methoxyphenyl]ethanone (63), which produced a 35% reduction in blood pressure and was similar in activity to nifedipine. At lower doses, however, 4-[bis(4-fluorophenyl)methyl]-1-[3-(4-chlorophenoxy)propyl]piperidine (93) was one of the most effective antihypertensive agents, producing reductions in blood pressure of 17 and 11% at oral doses of 10 and 3 mg/kg, respectively; 63 was inactive at 10 mg/kg.     

3--氟4-(2-芳基噻-唑4-基)苯基唑烷酮类化合物的合成及抗菌活性

目的设计并合成3--氟4-(2-芳基噻-唑4-基)苯基唑烷酮类化合物,初步评价其体外抗菌活性。方法以(R)-环氧氯丙烷和间氟苯基异氰酸酯为起始原料,通过新的合成路线制备了目标化合物;采用微量液体稀释法,测定目标化合物的体外抗菌活性。结果与结论合成了14个新化合物,其结构经1H-NMR、MS确认,10个化合物显示出不同程度的抗菌活性,化合物IXc和Xc的活性较好,有进一步研究的价值。     

9-(2-Fluorobenzyl)-6-(alkylamino)-9H-purines. A new class of anticonvulsant agents

Several substituted aryl and 6-alkylamino analogues of the anticonvulsant purine 9-(2-fluorobenzyl)-6-(methyl-amino)-9H-purine (1) were synthesized and tested for anticonvulsant activity against maximal electroshock-induced seizures (MES) in rats. Derivatives with a second fluoro substituent in the 5- or 6-position of the aryl moiety were very active with ip ED50's that ranged from 2 to 4 mg/kg. Congeners in which the purine 6-substituent was varied among a number of alkylamino groups possessed potent activity against MES that was comparable to or several times better than phenytoin.     

Pyridonecarboxylic acids as antibacterial agents. 9. Synthesis and antibacterial activity of 1-substituted 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8-naphthyridine-3- carboxylic acids

The title compounds (7a-e) with ethyl, 2-fluoroethyl, 2-hydroxyethyl, vinyl, or cyclopropyl groups, respectively, at C-1 were prepared by the method involving the Balz-Schiemann reaction of 2-(4-pyridyl)pyridine- and 7-(4-pyridyl)-1,8-naphthyridinediazonium tetrafluoroborates (15 and 27). The 1-ethyl, 1-(2-fluoroethyl), and 1-vinyl derivatives showed in vitro activities as potent as the corresponding 7-(1-piperazinyl) analogues against Staphylococcus aureus 209P JC-1 and Escherichia coli NIHJ JC-2 but were less active against Pseudomonas aeruginosa 12. Among the 7-(4-pyridyl) derivatives having the different C-1 substituent, 1-cyclopropyl derivative 7e was found to be the most active. In vivo efficacy of 7e was superior to that of enoxacin against experimental infections due to S. aureus 50774. Some aspects of structure-activity relationships associated with the C-1, C-6, and C-7 substituents were discussed.     

Syntheses of (R)- and (S)-2- and 6-fluoronorepinephrine and (R)- and (S)-2- and 6-fluoroepinephrine: effect of stereochemistry on fluorine-induced adrenergic selectivities

Several routes to the enantiomers of fluoronorepinephrines (1) and fluoroepinephrines (2) were explored. A catalytic enantioselective oxazaborolidine reduction and a chiral (salen)Ti(IV) catalyzed asymmetric synthesis of silyl cyanohydrins proved efficacious in the key stereo-defining steps of two respective routes. Binding studies of the catecholamines with alpha(1)-, alpha(2)-, beta(1)-, and beta(2)-adrenergic receptors were examined. The assays confirmed that fluorine substitution had marked effects on the affinity of (R)-norepinephrine and (R)-epinephrine for adrenergic receptors, depending on the position of substitution. Thus, a fluoro substituent at the 2-position of (R)-norepinephrine and (R)-epinephrine reduced activity at both alpha(1)- and alpha(2)-receptors and enhanced activity at beta(1)- and beta(2)-receptors, while fluorination at the 6-position reduced activity at the beta(1)- and beta(2)-receptors. The effects of fluorine substitution on the S-isomers were less predictable.     

芳酰基氟尿嘧啶衍生物的合成及其抗肿瘤活性

采用２－取代－５－氟－３Ｈ－４－嘧啶酮与芳酰氯在丙酮中于三乙胺存在下反应,合成了１７个２－取代－３－芳酰基－５－氟－４－嘧啶酮类化合物。目标化合和的的结构经ＩＲ、＾１Ｈ－ＮＭＲ、元素分析或ＭＳ确定,初步生物活性测定显示,部分化合物具有一定的抗肿瘤活性。